Hanmi Science
| Market cap | ₩3.9T |
| PE ratio | 26.10 |
| Forward PE | – |
| PB ratio | 3.68 |
| EPS | ₩2,207 |
| Dividend (yield) | ₩300 (0.52%) |
| Analysts (1–5) | – |
| Price target | – |
| Volume | 183,472 |
| Trading value | ₩10.4B |
| Day’s range | ₩54,200 – ₩57,700 |
| 52-week range | ₩25,600 – ₩61,000 |
| Foreign ownership KR | 1.25% |
| Foreign net buy (Oct 2) KR | +20,317 sh |
| Book value / share | ₩15,661 |
| Founded | 1973 |
Close (KRW) Foreign ownership, % of shares (right axis)
Foreign, institutional and retail net buying KR data
Shares by trading day; positive means net buying. Korea publishes investor-type flows for every stock — global sites such as Yahoo or StockAnalysis do not show them.
| Date | Close | Foreigners | Institutions | Retail | Foreign ownership |
|---|---|---|---|---|---|
| Oct 2 | ₩55,300 | +20,317 | +17,895 | −39,057 | 1.25% |
| Oct 1 | ₩52,700 | +3,914 | +3,871 | −12,464 | 1.22% |
| Sep 30 | ₩52,800 | +605 | +16,485 | −22,003 | 1.23% |
| Sep 29 | ₩52,200 | −4,446 | +10,877 | −7,448 | 1.23% |
| Sep 28 | ₩52,400 | −9,163 | +20,595 | −12,466 | 1.23% |
Financials
Annual, consolidated where available, KRW. Columns ending in E are analyst consensus estimates. Source: company filings (DART) via Naver Finance.
| Item | FY2023 | FY2024 | FY2025 | FY2026E |
|---|---|---|---|---|
| Revenue | ₩1.2T | ₩1.3T | ₩1.4T | ₩1.5T |
| Operating income | ₩124.5B | ₩98.9B | ₩138.7B | ₩178.3B |
| Net income | ₩115.1B | ₩56.7B | ₩117.7B | ₩173.5B |
| Operating margin | 9.97% | 7.70% | 10.22% | 12.05% |
| Return on equity | 15.22% | 7.30% | 13.13% | – |
| Debt-to-equity | 55.71% | 60.85% | 55.24% | – |
| EPS | ₩1,646 | ₩864 | ₩1,731 | ₩2,549 |
| Dividend per share | ₩200 | ₩300 | ₩300 | – |
Peers
| Samsung Biologics 207940 | ₩1,310,000 | −3.25% |
| Celltrion 068270 | ₩182,400 | −0.11% |
| Samsung Epis Holdings 0126Z0 | ₩371,500 | +1.78% |
| Hanmi Pharm 128940 | ₩523,000 | +3.36% |
| SK Biopharmaceuticals 326030 | ₩76,600 | +1.06% |
| Sam Chun Dang Pharm 000250 | ₩241,000 | +16.43% |
About
Hanmi Science is an operating holding company whose subsidiaries include a pharmaceutical maker. Besides its holding business, it runs a healthcare segment covering medical devices, food, beauty and IT solutions, added through a 2022 merger, and distributes drugs and health supplements through its HMP Mall. Founded in 1973, it was approved as a holding company in 2011.
Hanmi Science Co., Ltd. is listed on the KOSPI market of the Korea Exchange under the ticker 008930. Industry: Holding company.
Direct KRX access through a global broker, a US-listed ADR where one exists, or a Korea ETF — compared in our guide.
Data: Korea Exchange regular-session closing prices, volume and day’s range via Daum Finance, checked against a Naver Finance snapshot at the close; investor flows, foreign ownership and ratios via Naver Finance; company information from DART (Financial Supervisory Service). Updated after each Korean market close; ratios as of Oct 6, 2026; investor flows as of Oct 2, 2026. Delayed data, not investment advice.